Clinical Trial Update: AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating allogeneic human mesenchymal stem cells for fistulizing Crohn's disease via perifistula injections has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Fistulizing Crohn Disease

Drugs mentioned

• Allogeneic human mesenchymal stem cells (hMSC) (mesenchymal stem cells)

Snippet

Sponsor: Joshua M Hare | Conditions: Crohn's Disease, Fistulizing Crohn's Disease | Phase 1 | Status: WITHDRAWN